iSpecimen Inc's fundamentals are relatively healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 278/482 in the Software & IT Services industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
iSpecimen Inc's Score
Industry at a Glance
Industry Ranking
278 / 482
Overall Ranking
524 / 4562
Industry
Software & IT Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
iSpecimen Inc Highlights
StrengthsRisks
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.29M.
Overvalued
The company’s latest PE is -0.05, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 96.86K shares, decreasing 10.31% quarter-over-quarter.
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
Ticker SymbolISPC
CompanyiSpecimen Inc
CEOField (Katharyn)
Websitehttps://www.ispecimen.com/
FAQs
What is the current price of iSpecimen Inc (ISPC)?
The current price of iSpecimen Inc (ISPC) is 0.388.
What is the symbol of iSpecimen Inc?
The ticker symbol of iSpecimen Inc is ISPC.
What is the 52-week high of iSpecimen Inc?
The 52-week high of iSpecimen Inc is 3.380.
What is the 52-week low of iSpecimen Inc?
The 52-week low of iSpecimen Inc is 0.360.
What is the market capitalization of iSpecimen Inc?
The market capitalization of iSpecimen Inc is 3.79M.
What is the net income of iSpecimen Inc?
The net income of iSpecimen Inc is -12.50M.
Is iSpecimen Inc (ISPC) currently rated as Buy, Hold, or Sell?
According to analysts, iSpecimen Inc (ISPC) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of iSpecimen Inc (ISPC)?
The Earnings Per Share (EPS TTM) of iSpecimen Inc (ISPC) is -7.816.